TriangleNCT03833934 · OUTCOME
Prevalence of ALK Fusion
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 32 months
What was measured
To determine the prevalence of the ALK gene fusion in the cohort of patients with ALK-positive NSCLC with progression
Groups in this outcome
ALK-positive NSCLC With Progression
Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
| Group | Source count |
|---|---|
| ALK-positive NSCLC With Progression | 62 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ALK-positive NSCLC With Progression | 27 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 27
- denoms
- counts
- group Id
- OG000
- value
- 62
- units
- Participants
- description
- To determine the prevalence of the ALK gene fusion in the cohort of patients with ALK-positive NSCLC with progression
- groups
- description
- Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
- id
- OG000
- title
- ALK-positive NSCLC With Progression
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 32 months
- title
- Prevalence of ALK Fusion
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice